Standards & Best Practices

As part of its mission, SCB seeks to keep its stakeholders and the entire regenerative medicine community abreast of any relevant additions, updates, or other modifications to the standards landscape.

Needed Standards in Regenerative Medicine Report

In assessing the standards landscape as part of The Regenerative Medicine Standards Landscape report effort (see below), the community identified a strong need for more standards specific to regenerative medicine. In response, SCB, in partnership with Nexight Group, developed this Community Perspectives: Needed Standards in Regenerative Medicine report. The objective of the report is to outline standards needs identified by the community that could have the greatest benefit to the field and improve the safety and quality of regenerative medicine products.

This report is intended for regenerative medicine product manufacturers, researchers, clinicians, regulators, patient advocates, and other stakeholders interested in engaging in the standards development process to support advancement of standards that could drive improved safety and efficiency .

Regenerative Medicine Standards Landscape Report

In 2018, Nexight Group LLC and SCB co-authored The Regenerative Medicine Standards Landscape report with funding from the U.S. Food and Drug Administration (FDA). This report provides a snapshot of the current landscape for regenerative medicine standards. It outlines existing and in-development standards, providing a reference that individual organizations can use to identify available standards to improve their operations.

The first iteration of this report was developed in an accelerated 3-month timeframe and published in December 2017, with updates in February 2018 and in this Spring 2019 edition. Given the constantly-evolving nature of the field of regenerative medicine, SCB will continue to engage stakeholders to build on and refine this document in support of its mission.

Guidance and Regulations

Standards development requires close interaction with federal agencies that issue guidance documents and regulations:

  • Guidance: Formal statements of federal government agency policy with respect to laws or regulations

  • Regulations: Have the force and effect of law and are generally mandatory, setting out specific requirements that regulated products and entities must meet. In the United States, regulations are written (codified) in the Code of Federal Regulations (CFR) and published in the Federal Register (FR).

The following guidance documents and regulations are relevant to the regenerative medicine standards landscape.

cder draft guidance on the program for the recognition of voluntary consensus standards related to pharmaceutical quality

In February 2019, the FDA Center for Drug Evaluation and Research (CDER) issued the draft guidance for public review and comment: CDER’s Program for the Recognition of Voluntary Consensus Standards Related to Pharmaceutical Quality. This guidance document describes a proposed program at CDER to make a comprehensive listing of informally recognized voluntary related to pharmaceutical quality. The program, once established, will help promote innovation in pharmaceutical development and manufacturing and streamline the compilation and assessment of marketing applications for products regulated by CDER.

NOTE: The comment period for the guidance closed on April 15, 2019; the FDA has begun work on the final version of the guidance. 


On Tuesday, December 19, 2017, the FDA Center for Biologics Evaluation and Research (CBER) issued the draft guidance for public review and comment: Standards Development and the Use of Standards in Regulatory Submissions Reviewed in the Center for Biologics Evaluation and Research; Draft Guidance for Industry and Food and Drug Administration Staff. This guidance document describes what standards are and how they are developed by Standards Development Organizations (SDOs). The guidance document also addresses questions on how sponsors can use standards to facilitate product development and regulatory submissions, and acceptance of such use of standards by the FDA. The final version of the guidance was issued March 2019.


In 2012, the FDA amended the sterility test requirements for biological products. This rule provided manufacturers of biological products greater flexibility, as appropriate, and encouraged the use of the most appropriate and state-of-the-art testing methods for assuring the safety of biological products.